Official Positions for FRAX® Clinical Regarding Rheumatoid Arthritis

被引:32
|
作者
Broy, Susan B. [1 ]
Tanner, S. Bobo [2 ]
机构
[1] Chicago Med Sch, Rosalind Franklin Sch Med, N Chicago, IL USA
[2] Vanderbilt Univ, Med Ctr, Div Rheumatol & Allergy, Nashville, TN USA
基金
英国医学研究理事会;
关键词
Rheumatoid arthritis; osteoporosis; osteoporotic fracture; vertebral fracture; fracture risk; FRAX; BONE-MINERAL DENSITY; VERTEBRAL DEFORMITIES; RISK-FACTORS; FRACTURE RISK; INFLAMMATORY MARKERS; JAPANESE WOMEN; HIP-FRACTURES; OSTEOPOROSIS; ASSOCIATIONS; VARIABLES;
D O I
10.1016/j.jocd.2011.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis is the only secondary cause of osteoporosis that is considered independent of bone density in the FRAX (R) algorithm. Although input for rheumatoid arthritis in FRAX (R) is a dichotomous variable, intuitively, one would expect that more severe or active disease would be associated with a greater risk for fracture. We reviewed the literature to determine if specific disease parameters or medication use could be used to better characterize fracture risk in individuals with rheumatoid arthritis. Although many studies document a correlation between various parameters of disease activity or severity and decreased bone density, fewer have associated these variables with fracture risk. We reviewed these studies in detail and concluded that disability measures such as HAQ (Health Assessment Questionnaire) and functional class do correlate with clinical fractures but not morphometric vertebral fractures. One large study found a strong correlation with duration of disease and fracture risk but additional studies are needed to confirm this. There was little evidence to correlate other measures of disease such as DAS (disease activity score), VAS (visual analogue scale), acute phase reactants, use of non-glucocorticoid medications and increased fracture risk. We concluded that FRAX (R) calculations may underestimate fracture probability in patients with impaired functional status from rheumatoid arthritis but that this could not be quantified at this time. At this time, other disease measures cannot be used for fracture prediction. However only a few, mostly small studies addressed other disease parameters and further research is needed. Additional questions for future research are suggested.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [21] Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis
    Pietschmann, Peter
    Butylina, Maria
    Kerschan-Schindl, Katharina
    Sipos, Wolfgang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [22] Follow-up bone mineral density testing: 2023 official positions of the International Society for Clinical Densitometry
    Gani, Linsey U.
    Sritara, Chanika
    Blank, Robert D.
    Chen, Weiwen
    Gilmour, Julia
    Dhaliwal, Ruban
    Gill, Ranjodh
    JOURNAL OF CLINICAL DENSITOMETRY, 2024, 27 (01)
  • [23] Osteoporosis and Osteoarthritis, Rheumatoid Arthritis and Spondylarthropathies
    Clayton, Elizabeth Smelter
    Hochberg, Marc C.
    CURRENT OSTEOPOROSIS REPORTS, 2013, 11 (04) : 257 - 262
  • [24] Clinical Risk Factors for Osteoporosis in Ireland and the UK: A Comparison of FRAX and QFractureScores
    Cummins, N. M.
    Poku, E. K.
    Towler, M. R.
    O'Driscoll, O. M.
    Ralston, S. H.
    CALCIFIED TISSUE INTERNATIONAL, 2011, 89 (02) : 172 - 177
  • [25] Prevalence and Fracture Risk of Osteoporosis in Patients with Rheumatoid Arthritis: A Multicenter Comparative Study of the FRAX and WHO Criteria
    Choi, Sang Tae
    Kwon, Seong-Ryul
    Jung, Ju-Yang
    Kim, Hyoun-Ah
    Kim, Sung-Soo
    Kim, Sang Hyon
    Kim, Ji-Min
    Park, Ji-Ho
    Suh, Chang-Hee
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (12)
  • [26] Bone mineral density status in patients with recent-onset rheumatoid arthritis
    Ketabforoush, Arsh Haj Mohamad Ebrahim
    Aleahmad, Mehdi
    Qorbani, Mostafa
    Mehrpoor, Golbarg
    Afrashteh, Sima
    Mardi, Shayan
    Dolatshahi, Elahe
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2023, 22 (01) : 775 - 785
  • [27] Special report on the official positions of the International Society for Clinical Densitometry
    E. M. Lewiecki
    D. L. Kendler
    G. M. Kiebzak
    P. Schmeer
    R. L. Prince
    G. El-Hajj Fuleihan
    D. Hans
    Osteoporosis International, 2004, 15 : 779 - 784
  • [28] Special report on the official positions of the International Society for Clinical Densitometry
    Lewiecki, EM
    Kendler, DL
    Kiebzak, GM
    Schmeer, P
    Prince, RL
    El-Hajj Fuleihan, G
    Hans, D
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 (10) : 779 - 784
  • [29] Fracture in clinical studies of tofacitinib in rheumatoid arthritis
    Hansen, Karen E.
    Mortezavi, Mahta
    Nagy, Edward
    Wang, Cunshan
    Connell, Carol A.
    Radi, Zaher
    Litman, Heather J.
    Adami, Giovanni
    Rossini, Maurizio
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [30] Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis
    Adami, Giovanni
    Saag, Kenneth G.
    CURRENT RHEUMATOLOGY REPORTS, 2019, 21 (07)